1. Introduction {#s0005}
===============

Hepatoid carcinoma of the ovary (HCO) is a very rare group of extrahepatic aggressive tumors with similar hepatocarcinoma (HCC) clinical and pathological characteristics, unknown histogenesis, and most frequent in postmenopausal patients. This histopathologic variant is classified by some authors within the epithelial origin of ovarian tumors, however, there is still controversy about its origin. HCO was first reported in 1987 Ishikura and Scully ([@b0035]), who carried out a review of rare undifferentiated ovarian tumors, and found 5 cases with hepatocellular morphology and histologic characteristics without liver injury, 38 cases have been reported to date.

2. Case presentation {#s0010}
====================

A peruvian 27-year old female, childless, referring three months with pelvic pain, she had an abdominopelvic ultrasound reporting right adnexal mass. It was operated in her hometown on January 2016, performing right salpingo-oophorectomy. The pathology report was epithelioid malignant neoplasm suggestive of undifferentiated ovarian carcinoma, annex size was 10 cm and serum alpha fetoprotein (AFP) of 1210 ng/ml, for what it was referred to the National Institute of Neoplastic Diseases (INEN).

On admission, physical examination was normal, new reading plates was performed and reports: Primary hepatoid carcinoma of ovary ([Fig. 1](#f0005){ref-type="fig"}), fallopian tube without pathologic alterations or tumor involvement, ovarian capsule neoplasm free. No evidence of endodermal sinus component. Immunohistochemistry PANKERATIN (+), AFP (+), GLYPICAN (+), HER PAR 1 (+), SALL-4 (focal+) ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Immunohistochemical findings.

ABDOMINAL MR was made in March 2016 and report right annex absent, rest unchanged. Tumor markers: AFP: 10 ng/ml, Ca125: 10.05 U/mL, Ca19.9: 7.77 U/mL, CEA: 0.69, hCG \< 0,100 mIU/mL. For surgical indication, it was known that the staging need to be completed, however we took into account the age and desire to procreate of the patient, the possibility of disease recurrence was explained, and the final decision was a conservative surgical ovarian staging by laparoscopy on April 2016 (peritoneal cytology, bilateral pelvic lymphadenectomy, paraaortic lymphadenectomy, infracolic omentectomy and peritoneum biopsies). Pathology report: multiple biopsies and omentum negative, 0/19 pelvic lymphadenectomy and 0/6 retroperitoneal lymphatics. The clinical stage was IA, and tumor markers were negative after surgery. A multidisciplinary meeting was performed for determinate adjuvant treatment in an early stage case with complementary conservative surgery without active disease. At the time of the present case (2014), our country did not have the SALL-4 study and the decision of chemotherapy was like a germ cell tumor, based on age of presentation and tumor markers.

Began adjuvant chemotherapy at 12 weeks' post-surgery, with three courses BEP (bleomycin, etoposide and platinum) culminating in November 2016, remaining under observation with negative imaging studies and tumor markers nowadays.

3. Discussion {#s0015}
=============

The first report was in 1987, by [@b0035], they discovered five cases of ovarian tumors with cytological and morphology characteristics similar to hepatocarcinoma (HCC) without liver commitment. Age of presentation is 35--78 years, over 90% of cases present elevated AFP and Ca 125 can be raised in 60% of cases ([@b0005]).

The diagnosis is mostly in advanced clinical stages (III--IV), \<20% of patients have confined disease, and of those cases more than a half progress ([@b0005]). Macroscopically are multinodular, solid tumors, occasionally with cystic component, size between 5 and 35 cm (mean: 12 cm), usually unilateral, but 22% of cases are bilateral ([@b0005]). The association with alpha-fetoprotein (AFP) is over 90%, however, 8% of cases are negative ([@b0140]).

They have been described in various organs, most frequently at gastrointestinal tract (stomach) ([@b0185]), also in lungs, gallbladder, pancreas, bladder, kidney, ovaries and uterus. In the genital area, 75% of cases are present in ovary ([@b0020]), the absence of lesions in the liver parenchyma supports their diagnosis, but the presence of liver and ovarian lesions simultaneously makes the diagnosis very difficult especially when hepatocellular carcinoma rarely metastasizes to the ovary ([@b0185]). The median survival is 12 months, between the first and second year is 83% and 53% respectively ([@b0115]).

Macroscopic general features are tumors with solid and cystic component with white to yellow cut surface; as well as it is common to find hemorrhage and necrosis. Histologic features are a diffuse, trabecular/sinusoidal pattern and nested growth, which often coexist. Also, it can show extracellular hyaline bodies. The cytological features are polygonal cells with moderate to abundant eosinophilic cytoplasm, with distinct cell borders and central round vesicular nuclei with moderate to marked cytologic atypia and some of them with ≥1 nucleoli. Intracytoplasmic hyaline bodies can be observed. Also, frequent mitoses, including atypical forms are observed ([@b0100]). Inmunohistochemistry features are AFP, Hep-Par1, α-1-antitrypsin, glypican-3, albumin, ck7, ck19 and ck20 positive; while the Pan keratin and CK8 are focally positive; on the other hand, these tumors are negative for calretinin, inhibin, synaptophysin, estrogen receptor and progesterone receptor ([@b0165]). Differential diagnoses are the yolk sac hepatoid tumors that are SALL4 positive, this marker is more sensitive than classical IHC markers, such as placental-like alkaline phosphatase (PLAP), AFP, or glypican3, and strongly stains more than 90% of tumor cells. Positive staining for glypican3, AFP, and PLAP is seen in 100%, 95%, and 66% of cases, which does not occur in hepatoid ovarian carcinoma ([@b0120]). Another differential diagnosis are metastatic hepatocellular carcinomas that have a multinodular growth pattern; and Steroid cell tumors, which have androgenic manifestations and are smaller cells with vacuolated cytoplasm, positive for inhibin, calretinin, SF1, WT1 ([@b0165], [@b0120]).

Thirty-eight cases have been reported, and is still insufficient data to determine optimal treatment of these patients, there is no standard, most patients are treated with surgery (maximum cytoreduction) and adjuvant chemotherapy.

The use of biological therapy extrapolated in relation to hepatocellular carcinoma, sustainable data having little use, since, despite having pathological similarity between HCC and HCO these are biologically different, HCO has clinical aspect in relation to epithelial tumor. In the study by [@b0110] reported the use of sorafenib, and showed no effects in these patients, other reviews mention progression-free survival of 7 months.

We have compiled the reported cases of HCO since 1987 to the present ([Table 1](#t0005){ref-type="table"}), following the sequence performed by [@b0115], [@b0005], having 39 cases including our report. Of all these cases, our patient is the only one how comes out the usual scheme (age of presentation, laparoscopic conservation surgery and adjuvant treatment), she presented AFP 1210 ng/ml, following initial surgery was found in 10 ng/ml and after performing surgery and adjuvant chemotherapy AFP values have remained \<7 ng/ml. This case demonstrates that it is possible considerate conservation surgery in an early stage with good outcomes in relation to disease free survival.Table 1Clinical, laboratorial, pathological, immunohistochemical, treatment and outcomes of HCO.CaseAgeSite/size (cm)StageAfp ng/mlCa125 U/mlIchSurgeryResectionPost op. treatmentDissease controlOutcomeReference142L 6.4; R 5.4IIBNANAAFP+/AAT+/ALB+/ACT+TAH + BSO + APR0Ch-RTRelapse: 4 years - carcinomatosisDied (5 years)[@b0035]271L 20IIICNANAAFP+/AAT+/ALB+/ACT+PC + TAH + BSO + AP + OmR1RTPersistence: 3 months post op, parasigmoid tumorAlive (2 years)[@b0035]357R 10.5IIICNANAAFP+/AAT +/ALB+/ACT+TAH + BSO + Om + PARASPLENIC RESECTIONR1NAPersistence: 3 months post op, lower abdomen tumorDied (4 months)[@b0035]478NAIIIC2420 (post op)NAAFP+/AAT +/ALB+/ACT+BSO + COLECTOMY + POmR0MFLPersistence: 4 months post op, tumor in left lobe of the liverDied (8 months)[@b0035]568R 10IIINANAAFP+/AAT +/ALB+/ACT+BSO + COLECTOMY + POmR1Ch-RTRelapse: months, lesions at pancreas, liver, stomach, small bowel, abdominal lymph nodes, and spleen.Died (10 months)[@b0035]664R 18IA23,17058AFP+R-SOR0IP- CDDPNo progression during follow up periodAlive (2 years)[@b0075]762R 8.2IA2450NANANANAB/VLB/CDDP; CDDP/E; CTX/MMC/5-FUNADied (13 months)[@b0145]852NAIII2500ElevatedNANANACBDP/CTX/CDDPRelapseRecurred (7 months)[@b0010]943L 7; r 8IIIC74158CEA+/ALB+/EMA+/AFP +BSO + ATH + Om + RLNACDDP/EPIDX/IFXNo progression during follow up periodAlive (2 years)[@b0095]1072L 9.5; r 5.5III500 (postop)802AFP +ATH + BSO + RIGHT HEMICOLECTOMY + IOmR0CBDPRelapse: 5 months, clinical and biochemicalRecurred (6 months)[@b0125]1135L 35IIIA358NORMALAFP+L-SO + OMENTAL BIOPSY + ATH + R-SO + IOmR0CTX/CDDP/CBDP/E, PCTXLRelapse: 18 months, tumor at pelvis, lower abdomen, liver metastasesRecurred/died (18/22 months)[@b0080]1253L 9; R 8IIINA250NADSNACDDP/CTXRelapseAlive (12 months)[@b0155]1361L 12III73,08079.7AFP+/CK7+/AAT+/ACT+ATH + L-SO + POmR0IP CDDP; CDDP/5-FU/ERelapse: 5 months laboratorial, 7 months paraesplenic mass and intraperitoneal tumorDied (20 months)[@b0130]1464R 23IIIC90052.7AFP+ATH + BSO + BPL + Om + SEGMENTAL RESECTION OF SMALL BOWLR0CDDP/CTX; CDDP/PCTXL/RT; CDDP/PCTXLRelapse: 18 months, lesion in the mid‐line of the retroperitoneum. 2 years, paraaortic massRecurred/died (18/5 years)[@b0060]1536L 10IIICNA888AFP+/CEA+/AAT+ATH + BSO + BPL + Pao NODE BIOPSY + OmR0NANANA[@b0175]1669L 12IA589.511AFP+/CEA+/ALB+L-SOR0Patient declinedNANA[@b0150]1753L 10IIB257,522NORMALAFP+/CEA+/ALB+NAR0CBDP/PCTXLNo progression during follow up periodAlive (13 months)[@b0150]1876L 16IIB24,000NAAFP+/CEA+/ALB+ATH + BSO + PARTIAL COLECTOMYR0NoneNo progression during follow up periodAlive (4 years)[@b0150]1957R 13NA24,879NANAATH + BSO + OmNANANo progression during follow up periodAlive (3 years)[@b0160]2063R 16IA45484.59AFP+/CK7+/CEA+/ACT+ATH + BSO + POmR0CDDP/CTXNo progression during follow up periodAlive (7 months)[@b0180]2140R 11III32,3381297AFP+/CK7/CK8/CK18DSNdChTNo progression during follow up periodAlive (6 months)[@b0045]2242R 17IA600 (postop)NDAFP+/AAT+ATH + BSO + BPL + AP + IOmR0CBDP/PCTXLRelapse: 6 months, pulmonary metastatic tumorDied (16 months)[@b0055]2350L 10; R 8IIIC1.7538AFP+/CK+/EMA+/CK-7+ATH + BSO + Om + Tumor excision from the pelvis and ileostomyR2CDDP/PCTXL; CDDP/GMZ; DXRProgressDied (2 years)[@b0105]2465R 12III329,732401.9NAATH + BSO + OmR1CDDP/PCTXLNo progression during follow up periodNA[@b0030]2542L 11NDND70NAATH + BSO + OmR0NANANA[@b0190]2659L 18III73,6871599AFP +/CK+/CEA+ATH + BSO + POm + Low anterior resection of rectumR0BEPNANA[@b0040]2734R 14IIANORMALNORMALNADSNAChTNANA[@b0135]2842L 6INANAAFP+/CK7+/HEP PAR1+/AAT+/CEA-/INH-/CALRET-/ER-/PR -L-SO/ATH + R-SO + AP + OmR0Ch-RT following recurrenceRelapse: 2008, alive at follow up with local progressionNA[@b0025]2946L 4.5; R 6.5IIIgreater than30,000414CD99+/INH+/CALRET+/HepPar1-/AFP-/EMA-ATH + BSO + Om + BPL + DAFR1CBP/PCTXL- SORAFENIBRelapse: 1 month, retroperitoneal and pelvic lymphadenopathyNA[@b0110]3055L 11IIIC248.84168AFP+/HepPar1+/INH-/CALRET-/S100-/SYNAPTO-ATH + BSO + Om + DAFR1IP nitrogen mustard; DCTXL/NEDAPLATINPersistence abdominal diseaseAlive (10 months)[@b0065]3153L 7; R9IIIC3971247AFP+ (FOCAL)/CK7+/INH+ (FOCAL)/P53+/CA125-/PLAP-/HepPar 1-/CEA-/EMA-ATH + BSO + COm + RDP + PP + APR0HYPER ChT/CBP/PCTXL- Relapse: RTRelapse: metastasis in the L2 vertebraAlive (28 months)[@b0020]3257NA 12IIIC761124AFP+/INH-/ER-/PR-/PLAP-BILATERAL ADNEXA DISSECTION + Om + DISSECTION OF METASTATIC NODULES ON THE MESENTERY + DAFR0CBP/PCTXLNo progression during follow up period.Alive (15 months)[@b0170]3351R 9; l 8IVB2.237AFP-/HepPar1-/ER-/WT1-/P53+/P16+ATH + BSO + AP + TUMORECTOMY OF SIGMOID COLONR21° line: CBP/PCTXL-2° line: DCTXLProgress: Left SC LP +, carcinomatosis, metastatic LN at retroperitoneum, bilateral iliac chain and retrocrural area. Abdominal mass, pleural effusion.Died (6 months)[@b0140]3473L 24IIIC2396 (postop)NAAFP+/CK7+/HepPar1+(FOCAL)/SALL 4+/ARGINASE + CALRET--ATH + BSO + PARTIAL SMALL BOWEL RESECTIONR0CBP/PCTXLProgress: 7 weeks nodular mass in right upper quadrant, mass in the left side of the pelvis.Alive (26 months)[@b0115]3578R 9.9, L 4IVB150100AFP-/CK7-/HepPar1+/INH-/CALRET-/S100 -/SYNAPTO-/EMA-EXPLORATORY LAPAROSCOPY: PERITONEAL CARCINOMATOSISNoneCBP/PCTXLProgress: 1 month. Eight dorsal vertebra and pulmonar metastasic diseaseDied (1 month)[@b0085]3647NA 10/left lobe liver lesion 4NA6669144CK7+/HepPar1+/GLYPICAN +LEFT PARTIAL HEPATECTOMY + DSR0HIPEC: PNo progression during follow up periodAlive(22 months)[@b0090]3747R 10NA451NAAFP+ATH + BSOR0.Infiltration of marrow, pancytopenia.ChT: NANADied (3 months)[@b0050]3841L 5IIIC335114HepPar1+/ARGINASE+/GLYPICAN 3+/INH-/PAX8-/SALL 4-CORE BIOPSY OF OMENTAL NODULER2. C.Sorafenib. Progress: ChT CBP/PCTXLProgress: 2 monthsDied (2 months)[@b0070]3927R 10IA1210 (post op)10.05PANKERATIN+/AFP +/GLYPICAN+/HepPar 1+/SALL-4 focal +R-SO + PC + BPL + PAoL + IOm + PBR0ChT: BEPNo progression during follow up periodAlive (3 years)Present case[^1]

4. Conclusions {#s0020}
==============

Hepatoid carcinoma of the ovary is a rare neoplasm, highly aggressive, the most frequent presentation is in perimenopausal and postmenopausal age and usually the diagnosis it's in advanced disease. The treatment must be optimal cytoreductive surgery followed by chemotherapy. This is the first case reported in our institution and had conservative management. The clinical, imaging and laboratory evolution has been favorable with no evidence of disease relapse at 3 years follow-up.

Author contribution {#s0025}
===================

This case report it's the first one presented in our country. Being an unusual pathology makes the treatment a challenge, and the presentation of this case is in age range it's uncommon.

However, radical surgery has been the standard treatment in the cases reported internationally, this is the first case report with different management with conservative surgery under laparoscopic guidance and the disease free survival until now it's 3 years.

Declaration of Competing Interest
=================================

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

[^1]: **Abbreviations:** IHC, immunohistochemistry; AAT, a1 antitrypsin; ACT, a1 antichymotrypsin; AFP, a-fetoprotein; ALB, albumin; CALRET, calretinin; Chromo, chromogranin; CK7, cytokeratin 7; EMA, epithelial membrane antigen; ER, estrogen receptor; HepPar1, hepatocyte-paraffin antigen 1; INH, inhibin; PAX 8, paired box gene 8; PR, progesterone receptor; SALL 4, Spalt-like transcription factor 4; WT1, Wilms tumor 1; RT, radiotherapy. C, carcinomatosisDS, Debulking surgery; TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorectomy; R-SO, right salpingo-oophorectomy; L-SO: lenft salpingo-oophorectomy; Om, omentectomy; POm, partial omentectomy; COm, complete omentectomy; IOm, infracolic omentectomy; PC, peritoneal cytology; AP, appendectomy; RL, retroperitoneal lymphadenectomy; BPL, bilateral pelvic lymphadenectomy; PAoL, paraaortic lymphadenectomy; PB, peritoneum biopsies; RDP, right diaphragmatic peritonectomy; PP, pelvic peritonectomy; DAF, drainage of ascitic fluid; SC, supraclavicular; LN, lymph node; ChT: chemotherapy; CBP, carboplatin; PCTXL, paclitaxel; MFL, melphalan; EPIDX, epirrubicin, VLB, vinblastine; DCTXL, docetaxel; CDDP, cisplatin; BEP: bleomycin-etoposide-cisplatin; CDDP, cisplatin; CBDP, carboplatin; 5-FU, 5- fluorouracil; CTX, cyclophosphamide; GMZ, gemcitabine; DXR, doxorrubicine; MMc, mitomicine; IFX, ifosfamide; MMC, mitomicine; HIPER, hyperthermic intraoperative intraperitoneal chemotherapy; IP, intraperitoneal.NA, not available, R: right, L: left.
